Blood News and Research

RSS

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.

30 Nov 2010

Largest remote health monitoring project in the world launched in China

Canada-based IDEAL LIFE and China's Shandong NovaTech Biological Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer and medical products distribution network in China, announced the launch of the largest remote health monitoring project in the world, bringing wireless, remote health monitoring to the People's Republic of China.

30 Nov 2010

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

First Edition: November 30, 2010

Today's headlines include reports on congressional action on the Medicare doc 'pay fix' as well as results from a new poll related to how the public thinks Medicare should be addressed in the context of deficit reduction.

30 Nov 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010

Prescription rates for controlled medications double for teens, young adults

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have nearly doubled for those age groups in the past 14 years, according to a recent study published in Pediatrics. Overall, a controlled medication was prescribed for young adults at approximately one out of every six visits and for young adult by adolescents one out of every nine encounters.

30 Nov 2010

New review from JASN highlights hazards of fructose

More and more people have become aware of the dangers of excessive fructose in diet. A new review on fructose in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicates just how dangerous this simple sugar may be.

30 Nov 2010

Majority of Americans and Canadians are getting enough vitamin D and calcium, says report

The majority of Americans and Canadians are getting enough vitamin D and calcium to meet their needs, says a new report from the Institute of Medicine. Most people up to age 70 need no more than 600 international units, or IUs, of vitamin D per day, and those 71 and older may need as much as 800 IUs, the report finds. The amount of calcium needed ranges, based on age, from 700 to 1,300 milligrams per day.

30 Nov 2010

Fenwal's new Autopheresis-C software facilitates faster plasma-collection times

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that in a trial of its new Autopheresis-C® software, plasma-center professionals and donors reported faster plasma-collection times and an improved plasma-collection and donation experience. More than 90 percent of donors surveyed reported a decrease in their donation wait time. Donors who are more satisfied are more likely to donate regularly.

30 Nov 2010

FG-2216 drug offers new treatment option for kidney disease-related anemia

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

30 Nov 2010

New ultrasound-based treatment for varicose veins

Rowena Cheng, RN, has spent most of her 34-year career on her feet. Standing for long periods of time comes with the job of being a nurse. For Cheng, however, it exacted a physical toll: knotted, swollen blood vessels in the calf of her left leg.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

Amount of vegetables consumed in childhood correlated to arterial stiffness in adulthood

Eating a lot of fruits and vegetables as a child is associated with healthier arteries as an adult. The amount of vegetables consumed in childhood correlated to the amount of arterial stiffness in adulthood. Children who consistently eat lots of fruits and vegetables lower their risk of having stiff arteries in young adulthood, according to research reported in Circulation: Journal of the American Heart Association.

30 Nov 2010

Heart disease risk factors in childhood predicts likelihood of atherosclerosis as adults

Measuring heart disease risk factors in children at or after age 9 helped predict the likelihood of atherosclerosis in adulthood, according to a study in Circulation: Journal of the American Heart Association.

30 Nov 2010

biOasis commences research agreement with NRC

biOasis Technologies Inc. announced today that it has commenced a sponsored research agreement with the National Research Council of Canada. Under the terms of the agreement, the NRC will evaluate the ability of biOasis' compounds to cross the blood-brain barrier using time-domain in vivo optical imaging.

30 Nov 2010

Highmark, Alliance for a Healthier Generation collaborate to expand childhood obesity benefits

Thirty-nine percent of the children living in Pennsylvania are overweight and are at greater risk of developing such chronic diseases as diabetes, high blood pressure and heart disease than the generation before them. To continue its efforts to address childhood obesity, Highmark Inc. has collaborated with the Alliance for a Healthier Generation to expand its obesity benefits for children in 2011.

30 Nov 2010

Case Western Reserve University grants Thermalin Diabetes exclusive license on portfolio of insulin analogs

Case Western Reserve University has granted an exclusive license on a portfolio of insulin analogs to Thermalin Diabetes, LLC, which has assembled more than $3 million to support the development of these important new drugs.

30 Nov 2010